A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
Public ClinicalTrials.gov record NCT06041256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CLARA: A Phase 1/2 Multi-center, Randomized, Double-Masked, Prospective, Parallel-Arm Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
Study identification
- NCT ID
- NCT06041256
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Aurion Biotech
- Industry
- Enrollment
- 97 participants
Conditions and interventions
Conditions
Interventions
- AURN001 Combination Product
- Corneal Endothelial Cells Biological
- Y27632 Drug
Combination Product · Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 17, 2023
- Primary completion
- Oct 24, 2024
- Completion
- Apr 14, 2025
- Last update posted
- Dec 16, 2025
2023 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Aurion Biotech site | Little Rock | Arkansas | 72205 | — |
| Aurion Biotech site | Los Angeles | California | 90067 | — |
| Aurion Biotech site | San Francisco | California | 94158 | — |
| Aurion Biotech site | Atlanta | Georgia | 30339 | — |
| Aurion Biotech site | Indianapolis | Indiana | 46260 | — |
| Aurion Biotech site | Wichita | Kansas | 67206 | — |
| Aurion Biotech site | Minnetonka | Minnesota | 55305 | — |
| Aurion Biotech site | Garden City | New York | 11576 | — |
| Aurion Biotech site | Winston-Salem | North Carolina | 27157 | — |
| Aurion Biotech site | Cincinnati | Ohio | 45242 | — |
| Aurion Biotech site | Oklahoma City | Oklahoma | 73104 | — |
| Aurion Biotech site | Bala-Cynwyd | Pennsylvania | 19004 | — |
| Aurion Biotech site | Sioux Falls | South Dakota | 57108 | — |
| Aurion Biotech site | Houston | Texas | 77027 | — |
| Aurion Biotech site | Houston | Texas | 77055 | — |
| Aurion Biotech site | Norfolk | Virginia | 23502 | — |
| Aurion Biotech site | Seattle | Washington | 98125 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06041256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06041256 live on ClinicalTrials.gov.